Literature DB >> 16909911

Genome-wide analysis of DNA methylation changes in human malignancies.

C Plass1, D J Smiraglia.   

Abstract

DNA methylation is an epigenetic modification of the DNA sequence and thus does not change the genetic code but affects chromosomal stability and gene expression. DNA methylation patterns are heritable and can be passed on to the daughter cell. In this review, we briefly summarize our current knowledge on normal DNA methylation patterns and move on to discuss the current state of the field with respect to altered DNA methylation in cancer. We make a special attempt to address current questions relating to genome-wide DNA methylation patterns. Since DNA methylation is used as a therapeutic target in clinical studies, it is of utmost importance to define potential target sequences that could be used as diagnostic or prognostic markers. We conclude the review by outlining possible scenarios that may explain tumor type-specific DNA methylation patterns described by assays evaluating genome-wide levels of DNA methylation.

Entities:  

Mesh:

Year:  2006        PMID: 16909911     DOI: 10.1007/3-540-31181-5_9

Source DB:  PubMed          Journal:  Curr Top Microbiol Immunol        ISSN: 0070-217X            Impact factor:   4.291


  9 in total

1.  Association of the methylenetetrahydrofolate reductase C677T polymorphism and fracture risk in Chinese postmenopausal women.

Authors:  Xiumei Hong; Yi-Hsiang Hsu; Henry Terwedow; Genfu Tang; Xue Liu; Shanqun Jiang; Xin Xu; Xiping Xu
Journal:  Bone       Date:  2006-12-15       Impact factor: 4.398

Review 2.  Genome-wide epigenetic modifications in cancer.

Authors:  Yoon Jung Park; Rainer Claus; Dieter Weichenhan; Christoph Plass
Journal:  Prog Drug Res       Date:  2011

3.  Epigenetic repression of regulator of G-protein signaling 2 promotes androgen-independent prostate cancer cell growth.

Authors:  Dennis W Wolff; Yan Xie; Caishu Deng; Zoran Gatalica; Mingjie Yang; Bo Wang; Jincheng Wang; Ming-Fong Lin; Peter W Abel; Yaping Tu
Journal:  Int J Cancer       Date:  2011-06-09       Impact factor: 7.396

4.  Chemotherapeutic drug-induced ABCG2 promoter demethylation as a novel mechanism of acquired multidrug resistance.

Authors:  Eran E Bram; Michal Stark; Shachar Raz; Yehuda G Assaraf
Journal:  Neoplasia       Date:  2009-12       Impact factor: 5.715

5.  HOXB13, a target of DNMT3B, is methylated at an upstream CpG island, and functions as a tumor suppressor in primary colorectal tumors.

Authors:  Kalpana Ghoshal; Tasneem Motiwala; Rainer Claus; Pearlly Yan; Huban Kutay; Jharna Datta; Sarmila Majumder; Shoumei Bai; Arnab Majumder; Tim Huang; Christoph Plass; Samson T Jacob
Journal:  PLoS One       Date:  2010-04-29       Impact factor: 3.752

6.  Histone deacetylase inhibitor depsipeptide activates silenced genes through decreasing both CpG and H3K9 methylation on the promoter.

Authors:  Li-Peng Wu; Xi Wang; Lian Li; Ying Zhao; Shaoli Lu; Yu Yu; Wen Zhou; Xiangyu Liu; Jing Yang; Zhixin Zheng; Hui Zhang; Jingnan Feng; Yang Yang; Haiying Wang; Wei-Guo Zhu
Journal:  Mol Cell Biol       Date:  2008-03-10       Impact factor: 4.272

7.  Aberrant expression and localization of deoxyribonucleic acid methyltransferase 3B in endometriotic stromal cells.

Authors:  Matthew T Dyson; Toshiyuki Kakinuma; Mary Ellen Pavone; Diana Monsivais; Antonia Navarro; Saurabh S Malpani; Masanori Ono; Serdar E Bulun
Journal:  Fertil Steril       Date:  2015-08-01       Impact factor: 7.329

8.  NUP98-HOX translocations lead to myelodysplastic syndrome in mice and men.

Authors:  Christopher Slape; Ying Wei Lin; Helge Hartung; Zhenhua Zhang; Linda Wolff; Peter D Aplan
Journal:  J Natl Cancer Inst Monogr       Date:  2008

9.  Identification of candidate methylation-responsive genes in ovarian cancer.

Authors:  Laura Menendez; DeEtte Walker; Lilya V Matyunina; Erin B Dickerson; Nathan J Bowen; Nalini Polavarapu; Benedict B Benigno; John F McDonald
Journal:  Mol Cancer       Date:  2007-01-25       Impact factor: 27.401

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.